Adaptimmune Therapeutics plc has announced a regulatory issue concerning its compliance with Nasdaq's listing rules. The company received a notice from Nasdaq indicating that the minimum bid price of its American Depositary Shares (ADSs) had fallen below $1.00 per share for 30 consecutive business days, prompting an initial compliance period until April 30, 2025. Despite a subsequent extension to October 27, 2025, Adaptimmune was informed on August 14, 2025, that its securities had a closing bid price of $0.10 or less for ten consecutive trading days, placing it under the "Low Priced Stocks Rule." The company intends to request a hearing before the Nasdaq Hearings Panel to present a plan for compliance and seek further extension. During this process, its ADSs will continue to trade on the Nasdaq Capital Market under the symbol "ADAP." There is no assurance that the panel will approve the company's request for continued listing.